$136.64
-2.22-1.6%
Last update: Nov 10, 7:38 PM
Kymera Therapeutics Inc
KYMRNASDAQ
Kymera Therapeutics rose 126.7% from $61.26 to a 1-year high of $138.86, ahead of the S&P 500's +10.0%. Its worst day was Jun 2 (−9.1%), and its low came Nov 10 at $61.26.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Kymera Therapeutics shares rose 41.5%, while the S&P 500 fell 0.3%.
+41.5%, the year's best day, on 7M shares, the year's heaviest volume · S&P 500 −0.3%
Story events cover the past 12 months · Times ET
EPS of $-0.97 missed the $-0.78 estimate on $2.9M revenue (est. $16.2M).
+4.8% · S&P 500 −0.6%
EPS of $-0.71 beat the $-0.86 estimate on $34.4M revenue (est. $8.8M).
−0.5% · S&P 500 +1.0%
Kymera Therapeutics shares rose 16.6%, while the S&P 500 rose 0.1%.
+16.6% · S&P 500 +0.1%
EPS of $-0.62 beat the $-0.72 estimate on $65.0M revenue (est. $32.6M).
+1.0% · S&P 500 −0.2%
EPS of $-1.32 missed the $-1.27 estimate on $0.00 revenue (est. $3.6M).
+0.1% · S&P 500 −0.4%
Where it ended: a 1-year high close of $138.86 on Nov 9, 2026. Up next: Q4 2026 earnings on Feb 25, 2027 (EPS est. $-1.29, revenue est. $1.4M).
Nothing in the past 12 months.
All KYMR dividend historyReplay the year: the line draws itself and stops at each of the 6 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for KYMR and SPY from Benzinga historical bars. Not investment advice.
